Baird downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Neutral with a price target of $6.00 (from $29.00) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Axovant Sciences (AXON) PT Lowered to $9 at Evercore ISISeptember 26, 2017 12:07 PM Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains FocusSeptember 26, 2017 11:48 AM UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to NeutralSeptember 26, 2017 10:53 AM Oppenheimer Downgrades Axovant Sciences (AXON) to PerformSeptember 26, 2017 10:48 AM UPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital MarketsSeptember 26, 2017 9:49 AM Axovant (AXON) Says its Intepirdine Phase 3 MINDSET Trial in AD Did Not Meet its co-Primary Efficacy EndpointsSeptember 26, 2017 7:02 AM Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's DiseaseSeptember 26, 2017 7:00 AM